全文获取类型
收费全文 | 3648篇 |
免费 | 198篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 108篇 |
妇产科学 | 112篇 |
基础医学 | 491篇 |
口腔科学 | 30篇 |
临床医学 | 333篇 |
内科学 | 1003篇 |
皮肤病学 | 67篇 |
神经病学 | 313篇 |
特种医学 | 72篇 |
外科学 | 348篇 |
综合类 | 6篇 |
预防医学 | 157篇 |
眼科学 | 28篇 |
药学 | 318篇 |
中国医学 | 7篇 |
肿瘤学 | 460篇 |
出版年
2024年 | 3篇 |
2023年 | 24篇 |
2022年 | 73篇 |
2021年 | 99篇 |
2020年 | 75篇 |
2019年 | 89篇 |
2018年 | 121篇 |
2017年 | 80篇 |
2016年 | 93篇 |
2015年 | 97篇 |
2014年 | 135篇 |
2013年 | 179篇 |
2012年 | 265篇 |
2011年 | 305篇 |
2010年 | 150篇 |
2009年 | 168篇 |
2008年 | 285篇 |
2007年 | 259篇 |
2006年 | 236篇 |
2005年 | 243篇 |
2004年 | 213篇 |
2003年 | 194篇 |
2002年 | 195篇 |
2001年 | 30篇 |
2000年 | 34篇 |
1999年 | 26篇 |
1998年 | 32篇 |
1997年 | 19篇 |
1996年 | 27篇 |
1995年 | 10篇 |
1994年 | 14篇 |
1993年 | 16篇 |
1992年 | 16篇 |
1991年 | 6篇 |
1990年 | 14篇 |
1989年 | 8篇 |
1988年 | 2篇 |
1986年 | 3篇 |
1985年 | 4篇 |
1984年 | 4篇 |
1983年 | 4篇 |
1982年 | 6篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1977年 | 3篇 |
排序方式: 共有3862条查询结果,搜索用时 15 毫秒
81.
Purpose of Review
In this short review, the most common non-invasive neuromodulatory techniques will be described, along with their advantages and disadvantages and their application in headache. Available preventive treatments can be unhelpful or may have unpleasant side effects; moreover, the rate of response to preventive drugs does not exceed 50%, lower in chronic migraine; alternative options would be welcome. Though the concept of neuromodulation was originally developed with invasive methods, newer non-invasive techniques are appearing.Recent Findings
The novel neuromodulatory techniques have been developed with encouraging results: compared with traditional pharmacotherapy, advantages of non-invasive neuromodulation include reduced incidence of adverse effects, improved adherence, and safety and ease of use. The results are encouraging for acute or preventive treatment of different kinds of headache.Summary
A variety of neuromodulatory approaches is expanding fastly and has opened new possibilities for treatment of patients suffering from many forms of headache, especially those who have failed traditional pharmacotherapy. The non-invasive treatments can be seen as supplementing traditional management in refractory patients. Current study results are encouraging but preliminary and larger and more rigorous trials are needed to clarify benefit and mode of action.82.
Luigia Di Francesco Melania Dovizio Annalisa Trenti Emanuela Marcantoni Ashleigh Moore Peadar O’Gaora Cathal McCarthy Stefania Tacconelli Annalisa Bruno Sara Alberti Salvatore Gizzo Giovanni Battista Nardelli Genny Orso Orina Belton Lucia Trevisi Dan A Dixon Paola Patrignani 《British journal of pharmacology》2015,172(18):4575-4587
83.
Sganzerla P Bocciarelli M Savasta C Bonin M Tavasci E Fini M Perlasca E Alioto G Colombo F Passaretti B 《The Journal of invasive cardiology》2004,16(10):592-595
Carotid endarterectomy still represents the gold standard treatment of carotid artery bifurcation stenosis but percutaneous angioplasty with stenting is rapidly growing as a non-invasive alternative. In this paper we report the results of systematic application of carotid stenting performed in a cardiological setting, particularly as regards clinical management of patients and technical approach. One-hundred (100) procedures of carotid artery stenting (CAS) on 94 consecutive patients, both symptomatic and asymptomatic, with a carotid stenosis > 70%, were performed over a period of 30 months. The technical approach was directly derived from coronary angioplasty with use of large lumen guiding catheters, 0.014 in. intravascular guidewires and distal protection devices usually employed in coronary interventions. In 3 cases, a post-carotid endarterectomy restenosis and in 97 cases, a de-novo lesion, were treated respectively; in 71 cases, the degree of stenosis was 71-89% and in 29 cases, 90-99%. Cerebral protection was obtained with a distal to the lesion endovascular filter in 63 cases. Immediate technical success, i.e. residual stenosis of the treated vessel < 30% and no significant pathologic acceleration of blood flow (< 1.5 m/sec) at the Doppler ultrasound evaluation, was achieved in all procedures (100%). Ninety-six (96) procedures were totally uncomplicated; in-hospital cerebral complications were 1 TIA, 2 minor and 1 major strokes; at 30-day follow-up one additional major stroke occurred. Despite a particularly high incidence of comorbidities, neither unfavorable cardiological complications nor neurologic deaths were reported. Systematic CAS is a feasible treatment of the carotid artery bifurcation stenosis with high procedural success and low perioperative and short term complications. Its performance in a cardiological setting can combine satisfying procedural results and potentially successful handling of cardiovascular complications. 相似文献
84.
Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults 总被引:3,自引:0,他引:3
Insulin-induced hypoglycemia (ITT) is currently the "gold-standard" test for the diagnosis of adult growth hormone deficiency (GHD). ITT is often contraindicated, however, particularly in conditions that are also common in patients with suspected GHD. Used alone, GH-releasing hormone (GHRH) has no diagnostic value owing to within-subject variability and the inability to distinguish GHD from normal subjects. When combined with arginine, however, GHRH becomes a potent and reproducible test, which is unaffected by gender and aging, showing excellent specificity. The GHRH+ arginine (ARG) test distinguishes GHD patients from normal subjects and is at least as sensitive as ITT, provided that appropriate cutoff limits are considered. Its reliability for retesting GHD has also been demonstrated. The GHRH+ARG test can also be performed in a shorter procedure, resulting in potential for cost reduction. Synthetic GH secretagogues (GHSs) possess a strong and reproducible GH-releasing effect and synergize with GHRH. The combination of GHRH and a peptidyl GHS, such as hexarelin or GH-releasing peptide-6, has recently been shown as another reliable test for the diagnosis of adult GHD, again provided that the cutoff limit is appropriate to the potency of the test. Thus, GHRH combined with either arginine or GHS is a potential tool for the diagnosis of adult GHD. 相似文献
85.
86.
Broglio F Boutignon F Benso A Gottero C Prodam F Arvat E Ghè C Catapano F Torsello A Locatelli V Muccioli G Boeglin D Guerlavais V Fehrentz JA Martinez J Ghigo E Deghenghi R 《Journal of endocrinological investigation》2002,25(8):RC26-RC28
EP1572 UMV1843 [Aib-DTrp-DgTrp-CHO]) is a new peptido-mimetic GH secretagogue (GHS) showing binding potency to the GHS-receptor in animal and human tissues similar to that of ghrelin and peptidyl GHS. EP1572 induces marked GH increase after s.c. administration in neonatal rats. Preliminary data in 2 normal young men show that: 1) acute i.v. EP1572 administration (1.0 microg/kg) induces strong and selective increase of GH levels; 2) single oral EP1572 administration strongly and reproducibly increases GH levels even after a dose as low as 0.06 mg/kg. Thus, EP1572 is a new peptido-mimetic GHS with potent and selective GH-releasing activity. 相似文献
87.
Roberto Ronca Patrizia Alessi Daniela Coltrini Emanuela Di Salle Arianna Giacomini Daria Leali Michela Corsini Mirella Belleri Chiara Tobia Cecilia Garlanda Elisa Bonomi Regina Tardanico William Vermi Marco Presta 《The Journal of pathology》2013,230(2):228-238
Fibroblast growth factors (FGFs) exert autocrine/paracrine functions in prostate cancer by stimulating angiogenesis and tumour growth. Here dihydrotestosterone (DHT) up‐regulates FGF2 and FGF8b production in murine TRAMP‐C2 prostate cancer cells, activating a FGF‐dependent autocrine loop of stimulation. The soluble pattern recognition receptor long pentraxin‐3 (PTX3) acts as a natural FGF antagonist that binds FGF2 and FGF8b via its N‐terminal domain. We demonstrate that recombinant PTX3 protein and the PTX3‐derived pentapeptide Ac‐ARPCA‐NH2 abolish the mitogenic response of murine TRAMP‐C2 cells and human LNCaP prostate cancer cells to DHT and FGFs. Also, PTX3 hampers the angiogenic activity of DHT‐activated TRAMP‐C2 cells on the chick embryo chorioallantoic membrane (CAM). Accordingly, human PTX3 overexpression inhibits the mitogenic activity exerted by DHT or FGFs on hPTX3_TRAMP‐C2 cell transfectants and their angiogenic activity. Also, hPTX3_TRAMP‐C2 cells show a dramatic decrease of their angiogenic and tumourigenic potential when grafted in syngeneic or immunodeficient athymic male mice. A similar inhibitory effect is observed when TRAMP‐C2 cells overexpress only the FGF‐binding N‐terminal PTX3 domain. In keeping with the anti‐tumour activity of PTX3 in experimental prostate cancer, immunohistochemical analysis of prostate needle biopsies from primary prostate adenocarcinoma patients shows that parenchymal PTX3 expression, abundant in basal cells of normal glands, is lost in high‐grade prostatic intraepithelial neoplasia and in invasive tumour areas. These results identify PTX3 as a potent FGF antagonist endowed with anti‐angiogenic and anti‐neoplastic activity in prostate cancer. Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. 相似文献
88.
Emanuela Anastasi Lucia Manganaro Teresa Granato Pierluigi Benedetti Panici Luigi Frati Maria Grazia Porpora 《Disease markers》2013,35(5):331-335
Background. Surgical excision of ovarian endometriomas in patients desiring pregnancy has recently been criticized because of the risk of damage to healthy ovarian tissue and consequent reduction of ovarian reserve. A correct diagnosis in cases not scheduled for surgery is therefore mandatory in order to avoid unexpected ovarian cancer misdiagnosis. Endometriosis is often associated with high levels of CA125. This marker is therefore not useful for discriminating ovarian endometrioma from ovarian malignancy. The aim of this study was to establish if the serum marker CA72-4 could be helpful in the differential diagnosis between ovarian endometriosis and epithelial ovarian cancer. Methods. Serums CA125 and CA72-4 were measured in 72 patients with ovarian endometriomas and 55 patients with ovarian cancer. Results. High CA125 concentrations were observed in patients with ovarian endometriosis and in those with ovarian cancer. A marked difference in CA72-4 values was observed between women with ovarian cancer (71.0%) and patients with endometriosis (13.8%) (P < 0.0001). Conclusions. This study suggests that CA72-4 determination can be useful to confirm the benign nature of ovarian endometriomas in women with high CA125 levels. 相似文献
89.
Michael Feyder PhD Carina Plewnia BSc Ori J. Lieberman BSc Giada Spigolon PhD Alessandro Piccin PhD Lidia Urbina BSc Benjamin Dehay PhD Qin Li PhD Per Nilsson PhD Mikael Altun PhD Emanuela Santini PhD David Sulzer PhD Erwan Bezard PhD Anders Borgkvist PhD Gilberto Fisone PhD 《Movement disorders》2021,36(5):1137-1146
90.
Bernardi Laura Bertuccelli Margherita Formaggio Emanuela Rubega Maria Bosco Gerardo Tenconi Elena Cattelan Manuela Masiero Stefano Del Felice Alessandra 《European archives of psychiatry and clinical neuroscience》2021,271(1):199-210
European Archives of Psychiatry and Clinical Neuroscience - Fibromyalgia syndrome (FMS) is a complex pain disorder, characterized by diffuse pain and cognitive disturbances. Abnormal cortical... 相似文献